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Summary Lung tumours of non small cell pathology were cultured by clonogenic assay in several media.
Culture was successful in spleen conditioned medium, but only 57% grew and low plating efficiencies (PE)
meant that only 23% of the original number produced significant drug results. Comparison of rat erythrocyte
lysate (REL) medium with serum free defined medium (HITES) and HITES+10% FBS demonstrated clear
enhancement of PE in REL although growth was 100% successful in all these media. Ninety-three percent of
samples tested against drugs in REL produced significant results. A later comparison of REL with McCoy's
SA+rbc+hydrocortisone produced relatively poor culture success for these 3 media and equivocal growth
patterns. Low PE was attributed to age of rats used for rbc. Vindesine and cis-platinum cytotoxicity in spleen
conditioned medium were 61% and 15% sensitivity respectively. These do not concur with clinical experience
but the figures for overt resistance, at 39% and 69%, correspond with expected non-responders to these
regimes. Drug testing in REL produced figures correlating more closely with clinical performance at 45%
sensitivity to platinum and 36% of patients sensitive to both drugs, but the vindesine sensitivity at 55% is
again discrepant with performance of this drug as a single agent.
Cancer of the lung is a major cause of death in the
West of Scotland and poses a severe clinical
problem. Age at presentation has decreased and
women now constitute a significant proportion of
patients (Annual Report of the Registrar General
for Scotland, 1984). Combination chemotherapy
has contributed to substantial improvement in
response rates for small cell carcinoma of lung
(SCCL) whereas surgical resection is the accepted
treatment for non-small cell carcinoma (NSCCL).
This latter treatment may be followed, where
indicated, by radiotherapy but, at the present time,
chemotherapy of vindesine and cis-platinum is
reserved for palliative treatment of advanced
disease.
Hamburger & Salmon (1977) developed an assay
for clonogenic tumour cells in soft agar and its use
is now-widespread. Concurrent with an evaluation
of this method for ovarian tumour cells (Simmonds
& McDonald, 1984) it was decided to investigate
the feasibility of growing non-small cell cancer
specimens from thoracotomy patients. Such speci-
mens would then be tested against the drugs in
current use for inoperable patients. The information
gained would be useful in several ways. Firstly, it
could be established whether these tumours can be
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grown in agar with a sufficiently high 'take' rate to
allow drug sensitivity testing. Secondly, such drug
results could be compared against their present
clinical performance in order to validate the assay.
Finally, the information gained for individual
patients could be used in the event of relapse as an
index of likely response to chemotherapy.
Experience has shown that successful cultures
may not be made in sufficient numbers to justify
the time spent on in vitro drug testing. It was
therefore decided to use the Hamburger and
Salmon methodology, without change, for an initial
group of tumours and to investigate their drug
sensitivity. Any modifications of the medium would
then be made and comparisons made between
various media in order to select the most effective
for this system.
Carney et al. (1981) found that the use of a
serum-free hormone-supplemented medium (HITES)
would selectively permit establishment in culture of
cytologically positive specimens from small cell
cancer of lung. With the exception of an adeno-
carcinoma of lung, which survived for several
weeks, other tumour types failed to establish in this
system. However, it was felt that the nature of the
soft agar assay and its limited duration might lend
itself to growth enhancement of specimens by
HITES either alone or serum-supplemented, as
there is no requirement for establishment of a
primary cell line. Further modifications incorpor-
ating rat rbc as proposed by Courtenay and Mills
(1978) and Sheridan and Simmons (1981) would be
investigated as the haemoglobin moiety in such588 A.P. SIMMONDS et al.
systems has been shown to enhance plating
efficiency of other tumour types.
For organisational reasons August rats necessary
for the Courtenay methodology were not available
for several months and as the key to the effective-
ness of the blood cells is in their capacity to lyse in
culture, the rat erythrocyte lysate (REL) medium
developed by Sheridan and Simmons (1981) from
earlier work by Bradley et al. (1971) was used in
the first assay of alternative media.
Materials and methods
Tumour material
Material from 191 patients undergoing thoraco-
tomy at the Royal Infirmary was used. This
constituted solid tumour specimens only.
Collection ofcells
Tumours were transported in Hanks balanced salt
solution (HBSS) with penicillin and streptomycin.
They were then minced with crossed scalpels and
teased apart with needles. Large clumps were
removed by passage through 30,pm pore polyester
mesh and the cell suspensions so obtained were
passed through needles of decreasing size to 23
gauge and then washed twice by centrifugation in
HBSS with 10% heat inactivated foetal bovine
serum (FBS). Cell pellets were resuspended in
Hams F0 or RPM1-1640+10% FBS. Agitation by
repeated pipetting up and down resulted in single
cell suspensions. Any tumours which proved
resistant to this method of disaggregation were
suspended in 0.6% collagenase Type III following
initial mincing into 1 mm pieces. Incubation was at
37°C for a minimum of 3 h after which cells
released were washed by centrifugation and
resuspended as above.
Viable nucleated cell counts were determined by
trypan blue exclusion in a haemocytometer and
reference slides made of each cell suspension.
Culture assay
Medium I Cells were cultured as described by
Hamburger and Salmon (1977). One ml underlayers
containing 0.5ml of cell-free Millipore filtered
medium (RPM1-1640 conditioned by the adherent
spleen cells of mineral oil primed BALB/c mice) in
0.5% agar were prepared in 30mm Petri dishes.
Cells to be tested were suspended in 0.3% agar in
enriched CMRL-1066 medium with 15% horse
serum. Each plate received 2 x I05 viable cellsml 1
of agar: medium mixture and each assay was set up
in quadruplicate. One plate from each treatment
(day 0) was fixed in 3% glutaraldehyde BSS and a
score of any clumps made.
Medium 2 Cells were cultured in HITES medium
(Carney et al., 1981) consisting of RPM1-1640
supplemented with hydrocortisone 10nM, insulin
5 pgrml-1, transferrin 100pgml-1, 17 beta-oestra-
diol 10nM and sodium selenite 30nM. Viable cells
2 x 105 in 0.3% agar: HITES medium mixture were
plated over an underlayer of HITES in 0.5% agar.
Assays were set up in quadruplicate and day 0
plates prepared as above.
Medium 3 Cells were plated in HITES medium
exactly as detailed above but both underlayer and
overlayer were supplemented with 10% FBS.
Medium 4 REL (rat erythrocyte lysate) medium
was prepared according to the method of Sheridan
and Simmons (1981). Briefly, Dulbecco's MEM
(DMEM) was supplemented with L-asparagine,
insulin, hydrocortisone and tryptic soy broth to
which was added 6% FBS and rat erythrocyte
lysate, prepared as described below. No underlayer
was used and tumour cells (105-2 x l05) were
suspended in 1 ml of medium in 0.3% agar. Plates
were then treated as before.
Preparation ofrat erythrocyte lysate
Wistar rats were bled by cardiac puncture and the
blood collected into heparinised syringes. The buffy
coat was removed and the packed erythrocytes
washed 3 times with 0.85% sodium chloride. After
each wash, residual buffy coat cells were removed.
The washed packed sterile erythrocytes were lysed
in sterile distilled water (1:3v/v) and stored at 4°C.
Lysate was added at 1.5% final volume in the
medium.
Medium 5 McCoy's 5A medium supplemented
with insulin (3uml-1) and 10% FBS in 0.3% agar
was used to plate out 105 -2 x105 viable tumour
cells over an underlayer of the same medium in
0.5% agar containing August rat rbc at 1%
volume. Plates were prepared in quadruplicate as
before.
Medium 6 Medium 5+10 nM hydrocortisone.
Preparation ofrat red blood cells
August rats were bled by cardiac puncture and the
blood collected into heparinised syringes. The buffy
coat was removed by centrifugation,'the red cell
pellet resuspended in HBSS and washed twice more
by repeat centrifugation. The final red cell pellet
was made up to 20% in HBSS (1 part rbc to 4
parts HBSS). Aliquots were stored at 4°C for not
more than 3 weeks. Red cells used within the first
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hour to destroy residual nucleated cells. Cell pre-
parations were used at 1% volume in agar: medium
underlayers.
Incubation
All culture plates were incubated at 37°C in a 5%
C02/95% air humidified atmosphere for 12 days.
Scoring ofcultures
Cultures were examined with an inverted phase
microscope at x 100 and x 200. Aggregates of >32
cells were considered colonies and replicate plates
were stained with INT violet overnight at 37°C to
facilitate counting. Where day 0 counts of glutaral-
dehyde BSS fixed plates exceeded 20 per 105 cells
or 30 per 2 x 105, such assays were disregarded.
Counts less than these numbers were subtracted
from final counts and the plating efficiency (PE) of
each sample calculated from mean values of colony
counts for 3 plates.
Random sampling of colonies plucked from agar
and air dried on slides allowed comparison of
colony cells with those on reference slides of the
original suspension.
Drug sensitivity testing
Drugs used were cis-platinum diammine dihydro-
chloride (Neoplatin, Bristol Myers) and vindesine
(Eldisine, Eli Lilly). Values for in vitro drug con-
centrations used in the first study were those of
Alberts et al. (1980b). Later concentrations used
were those of 10% peak plasma concentration alone,
0.25 pgml-1 for cis-platinum and 0.02 pgml- 1 for
vindesine.
Single cell suspensions prepared as described
were adjusted to final concentrations of 106 or
2x106 viable cellsml-1 in Hams FO0 or RPMI-
1640 with 10% FBS. Aliquots of 0.5ml cell
suspension were then mixed thoroughly with 0.5ml
of double strength the appropriate drug concentra-
tion in the same medium and incubated at 37°C
without shaking for one hour. Drug was removed
by centrifugation at 400g for 10 minutes and the
cell pellet washed twice by centrifugation in HBSS
with 10% heat inactivated FBS. Control cultures
were treated similarly, but incubated in medium
alone. All cells were then suspended in the
appropriate overlayer medium and plated as
described.
At 12 days incubation, colony numbers were
counted and compared with controls. Results were
expressed as mean percentage survival of colonies
at each drug concentration. Where several
concentrations of drug were used, a linear dose
response curve was drawn and assessment of
response made using the sensitivity indices for area
under the curve described by Alberts et al.
(1980a, b).
For single drug doses at 10% peak plasma
concentrations, samples were judged sensitive if
percentage survival was <50% of control. Only
samples with a minimum of 30 colonies in control
plates for 2 x 105 cells plated and 15 colonies per
105 cells plated (PE=0.015%) were evaluated for
drug sensitivity.
Results
Culture medium 1 (Hamburger & Salmon, 1977)
Successful culture as measured by colony formation
of at least 10 colonies per dish at 12 days was
observed for all the histological non small cell
tumour types received. One hundred and nineteen
samples were received of which 113 yielded
sufficient cells for culture. Six of these were lost to
contamination and, of the remainder, 61 samples
grew (57%). Plating efficiencies ranged from less
than 0.01 to 0.16% but were predominantly low, 24
samples (39%) exhibiting plating efficiencies of 0.01
or less. Only one specimen had to be disaggregated
enzymatically.
Drug sensitivity, medium 1
Of the 53 samples with sufficient material for drug
sensitivity estimations, only 26 (49%) had plating
efficiencies high enough for drug results to be
significant (minimum 0.015%). This constituted
only 23% of original samples received.
The patterns of response to vindesine and cis-
platinum are illustrated in Figures 1 and 2.
Eighteen samples were tested against vindesine
(Figure 1) of which 11 (61%) were sensitive, the
remainder being markedly resistant. Twenty-six
samples were tested against cis-platinum (Figure 2)
of which 4 (15%) were sensitive, 18 were resistant
and 4 were classed as intermediate.
Of the 18 patient samples tested against both
drugs, dual sensitivity was recorded in 3 cases, dual
resistance in 5 and the remainder were made up of
vindesine sensitivity with platinum intermediate or
resistant (8) and vindesine resistance with platinum
intermediate or sensitive (2).
Culture - media 2, 3 and 4
As a direct consequence both of the poor growth
rate and low plating efficiencies observed in the
CMRL 1066/spleen conditioned medium tested, it
was decided to test a further group of samples in
alternative media incorporating the benefits of rat
erythrocyte lysate (REL) and of a medium known
to be highly selective for small cell tumours590 A.P. SIMMONDS et al.
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Figure 1 Patterns of in vitro response of non small
cell carcinoma of lung to vindesine. All patients were
untreated. Sensitivity is demonstrated in (a) and
resistance in (b).
(HITES). As an additional test, HITES and 10%
FBS was also used.
Twenty four samples of NSCCL were tested in
these media; 15 being tested in all 3 and a further 9
in REL and HITES +FBS alone. The results of
culture are shown in Table I.
Successful culture as measured by significant
growth (PE>0.015) was observed for 100% of
specimens in the 3 media. The lowest PE recorded
(0.015) was still significant in terms of possible drug
sensitivity testing. Plating efficiencies in REL
medium, however, were consistently higher than
in other media, ranging from 0.04 to 0.60% (23/24 >
0.05%) and were in every instance, bar one, a
b
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Figure 2 Patterns of in vitro response of non small
cell carcinoma of lung to cis-platinum. All patients
were untreated. Sensitivity is demonstrated in (a) and
resistance in (b).
minimum of 2 fold increase over that recorded in
HITES alone. There was also a clear enhancement of
growth over that observed in HITES +FBS, although
the differences were not consistently great. All
media produced more favourable results than
Medium 1.
Drug sensitivity - medium 4
As a result of successful culture in REL medium,
17 samples were carried forward for drug sensitivity
evaluation together with a further 28 samples
making 45 in all. Cells (105) were plated instead of
2x 105 and sensititivities were recorded as
described.
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Table I Plating efficiency of non-small cell cancer of
lung in 3 media: REL, HITES+10% FBS and HITES
alone.
Specimen Hites+ 10%
number REL FBS HITES
1 0.10 0.05 0.015
2 0.33 0.17 0.16
3 0.43 0.20 0.09
4 0.29 0.20 0.04
5 0.19 0.10 0.04
6 0.60 0.28 0.04
7 0.39 0.12 0.05
8 0.41 0.34 0.32
9 0.13 0.12 0.05
10 0.23 0.20 0.05
11 0.19 0.03 0.02
12 0.20 0.26 0.05
13 0.15 0.10 0.04
14 0.23 0.21 0.05
15 0.30 0.25 0.11
16 0.39 0.16 ND
17 0.53 0.29 ND
18 0.10 0.07 ND
19 0.08 0.06 ND
20 0.04 0.03 ND
21 0.17 0.10 ND
22 0.33 0.25 ND
23 0.16 0.12 ND
24 0.11 0.08 ND
ND=not done
Forty-two of the 45 samples (93%) produced
plating efficiencies high enough for significant drug
results (Table II). Nineteen of the 42 samples (45%)
were sensitive to cis-platinum and 23 (55%) sensi-
tive to vindesine. Thirty-six per cent, 15 samples,
were sensitive to both drugs with 11 samples
showing <20% survival. Similarly, 15 samples
(36%) were resistant to both drugs with 14 having
>60% survival and 12 of 14 with >80% survival.
A clear picture emerged indicating either marked
sensitivity or overt resistance to both drugs tested
in all but 12 cases.
Culture - media 5 and 6
Although the high percentage success rate with
REL medium was satisfactory, preparation was
lengthy and the medium had a short shelf life.
When August rats became available, a further
comparison of media was made in the hope that the
growth enhancing haemoglobin moiety of REL
medium might be more conveniently available from
these rat rbc which lyse in agar.
For 13 further specimens received, control culture
growth was compared in REL against McCoy's 5A
and rbc and an additional 7 samples were split
between these first 2 media and McCoy's 5A and
10nM hydrocortisone. Results for these control
cultures are seen in Table III. Six samples (30%)
failed to grow and plating efficiencies were much
lower than the previous evaluation with REL.
Table II Drug sensitivity of non-small cell cancer of lung (NSCCL) using REL medium.
Percentage Percentage Drug Percentage Percentage Drug
Sample survival survival sensitivity Sample survival survival sensitivity
number Vindesine (V) Platinum (P) V/P number Vindesine (V) Platinum (P) V/P
8 77 66 R/R 29 19 18 S/S
9 95 > 100 R/R 30 36 53 S/R
10 21 64 S/R 31 24 > 100 S/R
11 38 59 S/R 32 57 12 R/S
12 > 100 > 100 R/R 33 64 6 R/S
13 10 10 S/S 34 17 18 S/S
14 > 100 > 100 R/R 35 22 26 S/S
15 88 > 100 R/R 36 65 79 R/R
16 27 > 100 S/R 37 19 19 S/S
17 22 9 S/S 38 > 100 > 100 R/R
18 > 100 > 100 R/R 39 31 59 S/R
19 > 100 > 100 R/R 40 18 27 S/S
20 19 18 S/S 41 4 10 S/S
21 16 15 S/S 42 2 15 S/S
22 > 100 > 100 R/R 43 82 8 R/S
23 24 24 S/S 44 > 100 51 R/R
24 20 77 S/R 45 > 100 48 R/S
25 > 100 > 100 R/R 46 > 100 > 100 R/R
26 31 > 100 S/R 47 2 6 S/S
27 19 11 S/S 48 100 100 R/R
28 19 5 S/S 49 90 90 R/R
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Table III Plating efficiency of non-small cell cancer
of lung in 3 media: REL, McCoy's SA rbc+FBS,
McCoy's 5A rbc+FBS+hydrocortisone.
McCoy's SA
Specimen McCoy's 5A rbc+FBS+
number REL rbc+FBS hydrocortisone
53 0.30 0.2 ND
54 0.003 0.006 ND
55 0.06 0.03 ND
56 0.02 0.002 ND
57 0.13 0.23 ND
58 0.03 0.05 ND
59 0.03 0.06 ND
60 0.03 0.03 ND
61 0.02 0.02 ND
62 0.009 0.02 ND
63 NG NG ND
64 NG NG ND
65 NG NG ND
66 0.05 0.04 0.03
67 NG NG NG
68 0.03 0.03 0.03
69 NG NG NG
70 0.04 0.03 0.03
71 0.07 0.06 0.06
72 NG NG NG
NG =No growth; ND=Not done
Of the fir'st set of 13 samples, specimens 56 and
62 had significant growth only in REL or McCoy's
respectively. For the remaining specimens, growth
was significant in both media and the use of one or
the other did not change this.
Of the 7 samples where 3 media were compared,
3 specimens did not grow. With the exception of
No. 68, the PE was consistently marginally better
in REL, although significant in all samples which
grew.
Pathology
For all culture methods studied, no relationship
was observed between tumour type and either
successful culture, plating efficiency or drug
sensitivity. Predominant in tumour pathology were
squamous (65-66%) with adenocarcinomas 22-30%
and large cell anaplastic the remainder. Viabilities
of tumour cell suspensions prepared from samples
were frequently low, resulting in reduced viable cell
numbers for subsequent drug testing.
Comparison of cells from colonies with tumour
cells in the original suspension confirmed their
malignant nature, with squamous carcinomas con-
stituting the majority (66%) and adenocarcinomas
forming 30% of the total. No relationship was
observed between sample type and either success or
failure of culture.
Discussion
This study has shown that lung tumour material of
non-small cell pathology can be cultured
successfully by clonogenic assay and that such
cultures may be used to obtain in vitro sensitivity
measurements to drugs in current clinical use. The
relationship, however, between these results and
clinical experience has not been clearly established,
particularly with respect to vindesine.
Different media have been shown to have pro-
foundly different growth enhancing properties.
Medium 1, the original formula suggested for
tumour clonogenic assay by Hamburger and
Salmon (1977) supported growth in only 57% of
samples tested. Plating efficiencies, however, were
generally low such that only 61% of this group had
sufficient colony formation for significant drug
results. When a group of tumours was tested
against drugs, only 49% yielded significant results,
(23% of original tumour numbers received).
In contrast, marked growth enhancement as
measured by both increased plating efficiencies and
by numbers of tumours cultured successfully was
observed in media 2, 3 and 4 (HITES,
HITES+FBS and REL). REL, a relatively complex
medium, demonstrated up to 2 fold increase in PE
over the other media and when it was used for drug
testing 93% of samples produced significant drug
results.
For all these media, no relationship was observed
between tumour type and either successful culture
or plating efficiency. Squamous carcinomas, adeno-
carcinomas and large cell tumours grew in all
media used.
When REL medium was compared against
McCoy's rbc+hydrocortisone, disappointing results
were obtained in that only 70% of samples tested
grew. In addition, culture success was only 57%
when hydrocortisone was added to McCoy's
medium. Although this latter group of samples was
small and culture success was still superior to that
of medium 1, the lower plating efficiencies observed
meant that only 54% of specimens tested in 3
media would have yielded drug results and for 2 of
these, 56 and 62, the choice of medium would have
affected the outcome.
Successful and significant culture rates are central
to the usage of the clonogenic assay, as most drug
evaluations are set up at the same time as control
studies, because of small sample size. This entails
considerable work which may be wasted should the
culture fail to grow. However, when culture rates
are compared with our ovarian tumour experience
(Simmonds & McDonald, 1984) the percentage
successful culture, at 69% overall, is the same.
Kaiser et al. (1981) had 80% successful culture of
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37% of the tumours were lung primaries. Similarly,
Bertelsen et al. (1983) claimed 79% successful cul-
ture but here also, nearly 50% of the tumours
studied were metastatic. A higher growth rate is to
be expected with metastatic tumours as the process
of metastasis has already selected those sub-
populations with a greater potential for growth. All
tumours received by us were of primary lung origin
and if this type of tumour is compared, then
growth rates are 72% (Bertelsen et al., 1983) and
75% (Kaiser et al., 1981).
Our yield of drug results was 23% for medium 1,
93% for medium 4 and a potential for 60% and
57% in media 5 and 6 respectively. Kaiser et al.
had 56% drug results for primary tumours and
Bertelsen et al. had 72% for a similar group. What
is not clear about their results, however, is whether
plating efficiencies were significant. Both groups
accepted minimum PE of only 0.006 or 0.008 which
is exceedingly low and it is not stated to what
extent these minimum figures were exceeded.
Analysis of drug results shows that for medium
1, where area under the curve was used as an index
of sensitivity, 61% of samples were sensitive to
vindesine, and only 15% were sensitive to cis-
platinum. Thirty-nine percent of samples were
clearly resistant to vindesine, while 69% were resis-
tant to platinum exluding the 16% who showed
intermediate response. When REL medium was
used for drug study and evaluation of sensitivity
done on a percentage survival basis, 45% of
samples were sensitive to platinum and 55% sensi-
tive to vindesine. Similar pictures emerged from
both studies, that of either pronounced sensitivity
to drugs or of overt resistance and a superior
response rate to vindesine over platinum in vitro.
When individual patients are evaluated for their
sensitivity to both drugs, 36% were sensitive using
REL (medium 4) compared with 17% in medium 1.
Thirty-six per cent of patients were resistant to both
drugs with REL compared with 28% for medium 1.
These figures of 30-40% response rates do concur
with the clinical experience with these drugs (Elliott
et al., 1984). Additionally, although the figures
suggested for response in medium 1 for both vin-
desine and platinum are out of line with clinical
experience particularly as in vivo vindesine response
is poor, the figures suggested for resistance do
concur with those expected to be non-responders
(60-70%). Again, in this study, no relationship was
observed between tumour type and drug sensitivity
in vitro.
Kaiser et al. used I h drug exposures to drugs
tested with a sensitivity evaluation of <25% sur-
vival at peak plasma concentrations. Results for
platinum showed 33% response and 56% of lung
tumours tested showed response to at least one
drug in vitro. Our own observation is that 65% of
all samples tested show response to at least one
drug in vitro. We are satisfied, therefore, that this
test bears a relationship to projected clinical
response for both platinum and combination
performance, and as such, may be used to investi-
gate other drugs. What is not clear, however, is why
vindesine consistently gives superior in vitro sensi-
tivity results in this assay. This is not the clinical
experience, since vindesine as a single agent has not
proved itself in the management of NSCCL. It is
possible that the concentrations used in the first
assay were rather high and resulted in exaggerated
figures for sensitivity. This does not explain, how-
ever, either the low response rates to platinum in
this system or the fact that when the concentrations
were changed, vindesine again produced better
results (medium 4, REL) although the figures for
platinum response were closer to clinical experience.
With respect to growth in various media, the
poorer results for the second evaluation of REL
against McCoy's rbc require explanation. Blood
from August rats was used to prepare red cells,
both for REL and for addition at 1% in McCoy's
5A. All blood came from rats of the same age and
it is possible that they were past their prime.
It is our intention to continue lung tumour
culture using either McCoy's 5A+rbc+hydro-
cortisone or HITES+10% FBS with the cell con-
centrations and incubation times already described.
Restrictions of sample size allow only one cell
density to be plated and a pilot study established
linearity of colony formation over a wide range of
cell densities studied. Incubation time, at 12 days, is
sufficient to evaluate drug sensitivity, there being
no change in colony number between 10 and 21
days, when they begin to fragment. This brings the
assay within a time scale of clinical usefulness.
The case for the use of rat rbc as the only factor
producing significant increases in plating efficiency
and successful culture numbers has not been made.
HITES+ 10% FBS appears to be a useful alter-
native. A further option might be to use low (5%)
02 tension during incubation as suggested by
Courtenay and Mills (1978). However in a limited
number of cultures where this was tried (unpub-
lished) no differences were observed in this system.
With respect to the relevance of testing drugs used
only at the present time for inoperable patients,
it is clear that any future investigation would be
better directed towards factors affecting cytotoxicity
of existing drugs and to new drugs themselves.
The use of present chemotherapeutic regimes has
been validated both in vivo and in vitro and little
remains to be gained by further analysis of these
drugs alone.594 A.P. SIMMONDS et al.
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